Cargando…
The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD)
INTRODUCTION: Although substitutions of antiretroviral regimen are generally safe, most data on substitutions are based on results from clinical trials. The objective of this study was to evaluate the treatment outcomes of substituting antiretroviral regimen in virologically suppressed HIV‐infected...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810317/ https://www.ncbi.nlm.nih.gov/pubmed/29243388 http://dx.doi.org/10.1002/jia2.25016 |
_version_ | 1783299734791782400 |
---|---|
author | Jung, In Young Boettiger, David Wong, Wing Wai Lee, Man Po Kiertiburanakul, Sasisopin Chaiwarith, Romanee Avihingsanon, Anchalee Tanuma, Junko Kumarasamy, Nagalingeswaran Kamarulzaman, Adeeba Zhang, Fujie Kantipong, Pacharee Ng, Oon Tek Sim, Benedict Lim Heng Law, Matthew Ross, Jeremy Choi, Jun Yong |
author_facet | Jung, In Young Boettiger, David Wong, Wing Wai Lee, Man Po Kiertiburanakul, Sasisopin Chaiwarith, Romanee Avihingsanon, Anchalee Tanuma, Junko Kumarasamy, Nagalingeswaran Kamarulzaman, Adeeba Zhang, Fujie Kantipong, Pacharee Ng, Oon Tek Sim, Benedict Lim Heng Law, Matthew Ross, Jeremy Choi, Jun Yong |
author_sort | Jung, In Young |
collection | PubMed |
description | INTRODUCTION: Although substitutions of antiretroviral regimen are generally safe, most data on substitutions are based on results from clinical trials. The objective of this study was to evaluate the treatment outcomes of substituting antiretroviral regimen in virologically suppressed HIV‐infected patients in non‐clinical trial settings in Asian countries. METHODS: The study population consisted of HIV‐infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD). Individuals were included in this analysis if they started combination antiretroviral treatment (cART) after 2002, were being treated at a centre that documented a median rate of viral load monitoring ≥0.8 tests/patient/year among TAHOD enrolees, and experienced a minor or major treatment substitution while on virally suppressive cART. The primary endpoint to evaluate outcomes was clinical or virological failure (VF), followed by an ART class change. Clinical failure was defined as death or an AIDS diagnosis. VF was defined as confirmed viral load measurements ≥400 copies/mL followed by an ART class change within six months. Minor regimen substitutions were defined as within‐class changes and major regimen substitutions were defined as changes to a drug class. The patterns of substitutions and rate of clinical or VF after substitutions were analyzed. RESULTS: Of 3994 adults who started ART after 2002, 3119 (78.1%) had at least one period of virological suppression. Among these, 1170 (37.5%) underwent a minor regimen substitution, and 296 (9.5%) underwent a major regimen substitution during suppression. The rates of clinical or VF were 1.48/100 person years (95% CI 1.14 to 1.91) in the minor substitution group, 2.85/100 person years (95% CI 1.88 to 4.33) in the major substitution group and 2.53/100 person years (95% CI 2.20 to 2.92) among patients that did not undergo a treatment substitution. CONCLUSIONS: The rate of clinical or VF was low in both major and minor substitution groups, showing that regimen substitution is generally effective in non‐clinical trial settings in Asian countries. |
format | Online Article Text |
id | pubmed-5810317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58103172018-02-14 The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD) Jung, In Young Boettiger, David Wong, Wing Wai Lee, Man Po Kiertiburanakul, Sasisopin Chaiwarith, Romanee Avihingsanon, Anchalee Tanuma, Junko Kumarasamy, Nagalingeswaran Kamarulzaman, Adeeba Zhang, Fujie Kantipong, Pacharee Ng, Oon Tek Sim, Benedict Lim Heng Law, Matthew Ross, Jeremy Choi, Jun Yong J Int AIDS Soc Research Articles INTRODUCTION: Although substitutions of antiretroviral regimen are generally safe, most data on substitutions are based on results from clinical trials. The objective of this study was to evaluate the treatment outcomes of substituting antiretroviral regimen in virologically suppressed HIV‐infected patients in non‐clinical trial settings in Asian countries. METHODS: The study population consisted of HIV‐infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD). Individuals were included in this analysis if they started combination antiretroviral treatment (cART) after 2002, were being treated at a centre that documented a median rate of viral load monitoring ≥0.8 tests/patient/year among TAHOD enrolees, and experienced a minor or major treatment substitution while on virally suppressive cART. The primary endpoint to evaluate outcomes was clinical or virological failure (VF), followed by an ART class change. Clinical failure was defined as death or an AIDS diagnosis. VF was defined as confirmed viral load measurements ≥400 copies/mL followed by an ART class change within six months. Minor regimen substitutions were defined as within‐class changes and major regimen substitutions were defined as changes to a drug class. The patterns of substitutions and rate of clinical or VF after substitutions were analyzed. RESULTS: Of 3994 adults who started ART after 2002, 3119 (78.1%) had at least one period of virological suppression. Among these, 1170 (37.5%) underwent a minor regimen substitution, and 296 (9.5%) underwent a major regimen substitution during suppression. The rates of clinical or VF were 1.48/100 person years (95% CI 1.14 to 1.91) in the minor substitution group, 2.85/100 person years (95% CI 1.88 to 4.33) in the major substitution group and 2.53/100 person years (95% CI 2.20 to 2.92) among patients that did not undergo a treatment substitution. CONCLUSIONS: The rate of clinical or VF was low in both major and minor substitution groups, showing that regimen substitution is generally effective in non‐clinical trial settings in Asian countries. John Wiley and Sons Inc. 2017-12-15 /pmc/articles/PMC5810317/ /pubmed/29243388 http://dx.doi.org/10.1002/jia2.25016 Text en © 2017 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Jung, In Young Boettiger, David Wong, Wing Wai Lee, Man Po Kiertiburanakul, Sasisopin Chaiwarith, Romanee Avihingsanon, Anchalee Tanuma, Junko Kumarasamy, Nagalingeswaran Kamarulzaman, Adeeba Zhang, Fujie Kantipong, Pacharee Ng, Oon Tek Sim, Benedict Lim Heng Law, Matthew Ross, Jeremy Choi, Jun Yong The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD) |
title | The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD) |
title_full | The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD) |
title_fullStr | The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD) |
title_full_unstemmed | The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD) |
title_short | The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD) |
title_sort | treatment outcomes of antiretroviral substitutions in routine clinical settings in asia; data from the treat asia hiv observational database (tahod) |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810317/ https://www.ncbi.nlm.nih.gov/pubmed/29243388 http://dx.doi.org/10.1002/jia2.25016 |
work_keys_str_mv | AT junginyoung thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT boettigerdavid thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT wongwingwai thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT leemanpo thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT kiertiburanakulsasisopin thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT chaiwarithromanee thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT avihingsanonanchalee thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT tanumajunko thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT kumarasamynagalingeswaran thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT kamarulzamanadeeba thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT zhangfujie thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT kantipongpacharee thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT ngoontek thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT simbenedictlimheng thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT lawmatthew thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT rossjeremy thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT choijunyong thetreatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT junginyoung treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT boettigerdavid treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT wongwingwai treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT leemanpo treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT kiertiburanakulsasisopin treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT chaiwarithromanee treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT avihingsanonanchalee treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT tanumajunko treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT kumarasamynagalingeswaran treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT kamarulzamanadeeba treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT zhangfujie treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT kantipongpacharee treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT ngoontek treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT simbenedictlimheng treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT lawmatthew treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT rossjeremy treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod AT choijunyong treatmentoutcomesofantiretroviralsubstitutionsinroutineclinicalsettingsinasiadatafromthetreatasiahivobservationaldatabasetahod |